C

CSL

Develops and delivers biotherapies and vaccines

Executive Director - Hospital Marketing

Full-TimePosted on 10/22/2026
No salary listed
Expert
Bachelor's, MBA
King of Prussia, PA, USA
In Person
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A Bachelor of Science or Bachelor of Arts degree is required; an MBA is preferred.
  • At least 15 years of relevant healthcare sales, marketing, or related experience, including biologics, medical devices, or pharmaceuticals.
  • At least 8 years of U.S.-focused product management experience, including product or line-extension launches.
  • At least 7 years of people-management experience.
  • Demonstrated experience contributing business input to early-stage development projects.
  • Experience with buy-and-bill, inpatient hospital reimbursement, marketing or selling, and account management.
  • Understanding and prior experience of high-cost biologic commercialization and reimbursement.
Responsibilities
  • Lead two of CSL's largest products for marketing in North America Commercial Operations and serve as a member of the U.S. Marketing Leadership Team.
  • Lead a team of marketers focused on serving healthcare professionals and patients and collaborating to ensure continued market access to therapies.
  • Lead commercial planning and execution, life-cycle management decisions, and core and advanced marketing efforts for a multi-billion-dollar business in collaboration with Sales, Corporate Accounts, Business Operations, and Medical Affairs.
  • Work with Global Commercial Development, Clinical Research, and Regulatory Affairs to represent North America in decisions for the hospital franchise.
  • Establish and obtain approval for strategic direction and marketing activities across multiple product portfolios, including product and life-cycle management launches, and incorporate stakeholder input from Medical Affairs, Sales, Commercial Development, Clinical Research and Development, and Regulatory Affairs.
  • Develop innovative, competitive business plans for in-line and launch brands and manage marketing activities to ensure compliance with internal company and external requirements.
  • Lead development and execution of franchise and brand positioning, growth strategies, and tactics across all products in the franchise or therapeutic area; guide annual and multiyear strategic planning and gain management approval and organizational alignment.
  • Partner with Healthcare System teams on franchise and brand decisions to align channel strategies, pricing, and access strategy with brand objectives and financial goals.
  • Support strategic and tactical management of the therapeutic-area portfolio; develop annual business plans based on market definition, segmentation, business opportunities, and appropriate business levers.
  • Implement and measure commercial plans across multiple hospital products to maximize patient reach, revenue, and market share; ensure marketing representation on therapeutic-area business teams.
  • Lead budgeting, forecasting, and capability building for the hospital franchise; develop strategic-plan and manufacturing-plan forecasts with Healthcare System teams and Finance, incorporating stakeholder input, and ensure proper product inventory management.
  • Develop and sustain an innovative, collaborative, high-performance culture; recruit, develop, and advance marketing talent.
  • Make recommendations on brand and portfolio life-cycle management and gain alignment from stakeholders, including senior leadership.
  • Participate in the Global Therapeutic Area Leadership Team and work with global partners to identify product opportunities and accelerate packaging, administration, new product, and line-extension concepts for the U.S. market.
  • Contribute to early-stage product development to define Target Product Profiles and Target Labeling.
  • Ensure U.S. Commercial Operations input is provided to Target Product Profiles, clinical research protocols, and Target Labeling through appropriate channels; represent regional priorities and ensure North American Commercial Operations positions are reflected in key projects.
  • Build relationships with external customers, including thought leaders and patient advocacy groups, and manage and develop agency relationships in support of key initiatives.
  • Select and refine vendors for therapeutic-area programs and projects and ensure alignment with therapeutic-area marketing teams.
  • Oversee and manage direct and indirect reports, including annual objective setting, mid-year and year-end reviews, coaching and mentoring, employee development, recruitment, selection, and talent development.
  • Manage, direct, and measure team members' work on an ongoing basis and provide timely constructive feedback to ensure work meets or exceeds company standards.
  • Liaise with Government Reporting, Legal, and Compliance to ensure marketing programs comply with requirements.
  • Ensure proper staff assignments and timely completion of appropriate training.
  • Report to the Vice President of Marketing, U.S., and work with North America and CSL leadership to achieve franchise business objectives.
Desired Qualifications
  • Experience in multiple therapeutic marketing or commercialization areas.

About the company

CSL is a global biotechnology company that develops and delivers biotherapies and influenza vaccines. It focuses on plasma-derived and recombinant therapies for rare and serious diseases and sells to healthcare providers, hospitals, and governments across the Americas, Asia Pacific, and Europe. Its product range includes treatments for rare diseases, influenza vaccines, and antivenoms, produced through its R&D, manufacturing, and distribution operations. CSL differentiates itself by offering the broadest portfolio of plasma-derived and recombinant therapies and by leveraging its global footprint and emphasis on diversity to reach diverse markets. The company’s main goal is to save lives and protect health by expanding access to high-quality therapies and vaccines worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Parkville, Australia

Founded

1916

Get referred to CSL

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • CSL reported US$176 million FY26 cost savings, ahead of its transformation target.
  • US military flu-vaccine exceptions restored some demand after April 2026 mandate cuts.
  • VarmX’s 2029 coagulation program gives CSL a new high-value pipeline beyond plasma.

What critics are saying

  • FY26 statutory loss hit US$2.6 billion after US$7.1 billion impairments and restructuring.
  • CSL plans US$400 million FY27 savings, implying more closures, layoffs, and execution friction.
  • The U.S. plasma turnaround depends on Horizon 2; failure risks long-term margin collapse.

What makes CSL unique

  • CSL’s FY26 revenue reached US$15.8 billion across plasma, vaccines, and Vifor.
  • Seqirus’ AUJEMFLU won UK and European approvals, backed by Lancet Phase 3 data.
  • HEMGENIX remains Europe’s first approved hemophilia B gene therapy, strengthening CSL Behring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

1%
PR Newswire
Oct 21st, 2026
CSL appoints ViiV Healthcare chief Deborah Waterhouse as CEO on $1.9M base salary

CSL Limited has appointed Deborah Waterhouse as chief executive officer and managing director, effective February 1, 2027. The board's decision followed a global search and was unanimous. Waterhouse has led ViiV Healthcare, an HIV specialist majority owned by GSK, since 2017. ViiV had sales of £7.7 billion in GSK's 2025 financial year. She also serves as president of GSK Global Health and previously ran GSK's US vaccines and primary care businesses. Her base salary will be £1,500,000 a year. She will stay based in the UK. Gordon Naylor will remain interim chief executive until then, before returning to the board as a non-executive director.

Yahoo Finance
Oct 8th, 2026
CSL to roll out Haemonetics' NexSys devices across all US plasma centres by end of 2027

Haemonetics shares jumped 12% after the company announced CSL now expects to move all of its current US plasma collection centres to Haemonetics' NexSys devices by the end of 2027. The deal, first disclosed in August, was initially limited to only a portion of CSL's US centres with no timeline. The expanded agreement is significant because losing CSL previously flattened Haemonetics' growth. In fiscal 2026, the company's organic revenue growth was just 1.1%, compared to 9.5% excluding lost CSL sales. Following the surge, Haemonetics trades at approximately 21 times forward earnings, above its five-year average of 19.1 times. The deal is non-exclusive with no minimum purchase requirements, meaning CSL can still modify scope and timing. Management plans to provide further details during its November earnings call.

Pharma Dispatch
Oct 6th, 2026
CSL raises $1.5B from US bond investors to refinance debt

CSL has raised US$1.5 billion through corporate bonds issued in the United States to refinance existing debt. The Australian biotechnology company turned to offshore debt markets for the transaction. The bond issuance allows CSL to manage its capital structure by replacing current borrowings with new financing secured from US investors.

CSL
Sep 21st, 2026
CSL partners with VarmX in a strategic collaboration and option agreement to develop first-in-class investigational coagulation treatment

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

PR Newswire
Sep 10th, 2026
CSL Seqirus' triple-enhanced flu vaccine shows superior protection for older adults in Lancet study

CSL Seqirus has published Phase 3 study results in The Lancet Infectious Diseases for its MF59-adjuvanted cell-based higher-dose quadrivalent influenza vaccine for older adults. The vaccine, marketed as AUJEMFLU, combines three proven approaches: MF59 adjuvant, cell-based manufacturing, and higher-dose formulation. The randomised study enrolled 7,699 adults aged 50 and older across eight countries. Results demonstrated superiority versus an adjuvanted egg-based comparator across all four influenza strains and age groups. The vaccine showed non-inferiority versus a recombinant vaccine for three of four strains in the 50-plus age group and all four strains in those aged 65-plus. The trivalent formulation received approval from the UK's MHRA and the European Commission earlier this year for adults aged 50 and above. Regulatory submissions have been made in multiple markets.